Novo Nordisk Holds 2026 Outlook As FDA Drug Review Extends
Danish drugmaker Novo Nordisk announced that the U.S. approval of its haemophilia A drug denecimig will be delayed beyond the third quarter due to ongoing fixes at a manufacturing site. The FDA has indicated its review of the biologics license application is still underway.